BAUSCH & LOMB'S OPCON A TO BE AVAILABLE OVER-THE-COUNTER
BAUSCH & LOMB'S OPCON A TO BE AVAILABLE OVER-THE-COUNTER by the end of 1994 following FDA's approval of the company's Rx-to- OTC switch application on June 8. The antihistamine/decongestant eye drops (pheniramine .315%/naphazolinc HCl .027%) "will be available in food and drug stores and mass merchandise outlets across the country by late 1994," Bausch & Lomb said. The NDA (20- 065) switch application, which was filed in March 1990, included clinical trial data and manufacturing information, Bausch & Lomb said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth